The Centers for Disease Control and Prevention (CDC) on Saturday released new guidelines saying that people with underlying health conditions will receive a coronavirus vaccine.
The guide explaining “adults of any age with underlying health conditions are at increased risk for severe COVID-19-induced virus infection. ”
So the CDC added that these vaccines have been approved by the Food and Drug Administration (FDA) “they may be given to people with an underlying health condition as long as they have not had any serious allergic reactions to any of the ingredients in the vaccine. ”
The CDC explained that people with weakened immune systems as a result of illness or other medication may be able to get the COVID-19 vaccine, but should be aware that there is limited safety data available about the effect of the vaccines on these people.
Furthermore, although people living with HIV have been included in clinical trials, safety data for this group are not yet available.
The CDC also said in its guidance Saturday that people with autoimmune conditions can take the vaccine, although data are not currently available for vaccine safety in this demographic.
Those who have experienced Guillain-Barre syndrome – a condition in which the body attacks parts of its own nervous system – can receive the vaccine doses. The guidelines add that, following vaccination during clinical trials, there were no cases of the syndrome.
People who have experienced Bell ‘s palsy before – a condition that causes muscle weakness in one side of the face – can also get vaccinated. Some participants developed a Bell’s palsy clinical trial after receiving the vaccine, but it did not occur at a higher-than-expected rate in the general population.
Despite the beginning of the release of the Pfizer / BioNTech and Moderna vaccines, the CDC recommends that people receiving the vaccine should continue to follow conventional coronavirus health and safety protocols, such as tuberculosis. mask, social distance and avoiding crowds.
According to the CDC, nearly 2 million people received the first dose of coronavirus vaccine as Saturday. Both vaccines developed by Pfizer and BioNTech and the one from Moderna require two doses to be given several weeks apart.
Final test data on both vaccines showed that COVID-19 inhibition had a efficacy of around 95 percent, however Moderna vaccine has an 86 per cent efficacy for those over 65.
Priority was given to health care workers in the initial rollout of the vaccine, and the CDC Advisory Committee on Vaccination Practices (ACIP) voted last week to advise the CDC to include the 75 and older and specialty face-to-face staff, including emergency responders and teachers, in the next phase of coronavirus vaccines.